EyePoint Pharmaceuticals Conference Call Summary Company Overview - **Company**: EyePoint Pharmaceuticals (NasdaqGM:EYPT) - **Lead Program**: DURAVYU, a small molecule tyrosine kinase inhibitor (vorolanib) in Durasert E formulation - **Current Trials**: Four ongoing Phase III trials for retinal diseases, specifically: - Wet Age-Related Macular Degeneration (AMD): LUGANO and LUCIA - Diabetic Macular Edema (DME): COMO and CAPRI - **Confidence in Trials**: High confidence based on robust Phase II results [4][5][11] Key Findings from Trials - **Phase II Results**: - DAVIO 2 trial showed non-inferiority in visual acuity compared to EYLEA, with no significant safety issues [5][6] - Average improvement of 2.1 letters with DURAVYU versus 1.7 letters for EYLEA [7] - 80% reduction in treatment burden, with two-thirds of eyes not requiring supplements for 6 months [7][14] - **Safety Profile**: Over 190 patients dosed with no safety signals or serious adverse events (SAEs) attributable to DURAVYU [6][22][57] Ongoing Phase III Trials - **Enrollment**: - LUGANO: 432 patients - LUCIA: 475 patients - Rapid enrollment completed in about seven months for each trial [9][10] - **Dosing Schedule**: Patients receive DURAVYU every six months; retention rates are low (5% in LUGANO, 4% in LUCIA) [11][12] - **Expected Readouts**: - LUGANO: Top-line results expected around August 2026 - LUCIA: Results expected approximately two months later [11] Treatment Burden and Efficacy - **Reduction in Treatment Burden**: - Primary endpoint includes a significant reduction in treatment burden, with expectations of a 40% reduction based on Phase II data [14][37] - Statistical superiority requires only a 7-8% reduction in treatment burden [37] - **Commercial Perspective**: Positive visual acuity change is important for market acceptance, but non-inferiority is the primary goal [30][31] Legal Matters - **Competitor Misrepresentation**: EyePoint has pursued legal action against a competitor for misrepresenting DURAVYU data, emphasizing commitment to fair development and patient care [22][23] Financial Position - **Cash Position**: - Over $300 million in cash at the end of the previous year - Cash runway expected to last into Q4 2027, covering ongoing trials and NDA preparations [65][66] Conclusion - EyePoint Pharmaceuticals is optimistic about the ongoing trials for DURAVYU, with a strong safety profile and promising efficacy results. The company is well-positioned financially to support its clinical programs and navigate competitive challenges in the market.

Company Overview - EyePoint Pharmaceuticals is a biotechnology company focused on innovative sustained-release drug delivery systems for ocular diseases, particularly chronic and severe retinal conditions [5] - The company generates revenue primarily through product sales and strategic collaborations, with a product pipeline that includes ILUVIEN, YUTIQ, DEXYCU, and EYP-1901 [8] - EyePoint's main customers are healthcare providers and ophthalmologists treating retinal conditions in the United States, China, and the United Kingdom [8] Financial Performance - As of the latest report, EyePoint's market capitalization is $1.1 billion, with a revenue of $31.37 million for the trailing twelve months (TTM) [4] - The company reported a net income loss of approximately $231.96 million (TTM) as it continues to invest heavily in research and development [4][9] - EyePoint ended the year with about $306 million in cash and investments, sufficient to fund operations into late 2027 [9] Recent Developments - Parkman Healthcare Partners disclosed a new position in EyePoint, acquiring 1,088,033 shares in the fourth quarter, which increased the position's value by $19.88 million [2] - EyePoint shares have surged by 93% over the past year, significantly outperforming the S&P 500's 20% gain during the same period [7] - The company is advancing DURAVYU, a sustained-release therapy for serious retinal diseases, with Phase 3 trials currently enrolling over 900 patients and topline data expected in mid-2026 [7] Market Position - EyePoint is positioned to compete in a large ophthalmology market, which is currently dominated by frequent anti-VEGF injections [9] - The company’s differentiated product pipeline and strategic alliances support its leadership in ophthalmic therapeutics [5]

Core Viewpoint - Eyepoint Pharmaceuticals is making significant progress with its lead retinal candidate DURAVYU, which is expected to provide top-line data in wet age-related macular degeneration (wet AMD) by mid-2026, while also advancing pivotal studies in diabetic macular edema (DME) [3][4][21] Clinical Profile - DURAVYU's differentiation is attributed to its six-month dosing potential via standard in-office intravitreal injection, its delivery technology, and a novel multi-mechanism of action (multi-MOA) that inhibits VEGF, PDGF, and IL-6 via JAK1 without TIE-2 inhibition [1][7] - The clinical program has shown no safety signals across more than 190 patients in completed Phase 1 and Phase 2 trials, with consistent safety profiles in ongoing Phase 3 trials [2][6] Financial Overview - As of year-end 2025, the company reported cash and investments of $306 million, which is expected to fund operations into Q4 2027, despite a decline in revenues and an increase in operating expenses due to Phase 3 activities [5][16] - Total net revenue for Q4 2025 was $0.6 million, down from $11.6 million in the prior year, primarily due to deferred revenue recognition [17] - For the full year 2025, total net revenue was $31 million, compared to $43 million in 2024, with operating expenses rising to $275 million from $189 million [20] Safety Monitoring - The safety profile of DURAVYU includes low intraocular inflammation rates (~1%) and cataract/floaters rates comparable to control, with ongoing internal masked reviews and independent Data Safety Monitoring Committee (DMC) oversight [6][10] - Adverse events reported include cataracts in 5.8% of patients and vitreous floaters in 5.2%, consistent with intravitreal injection studies [9][18] Regulatory and Biomarker Work - The company is conducting two identical Phase 3 wet AMD trials and does not plan to alter its approach regarding regulatory pathways, emphasizing a non-inferiority strategy [11] - Additional biomarker data related to the JAK1 receptor and downstream IL-6 effects will be presented at ARVO in May, with ongoing studies assessing human impact [12] Commercial Readiness - The company is preparing for the launch of DURAVYU, focusing on market positioning, pricing research, and patient access [13] - Eyepoint has a cGMP manufacturing facility in Massachusetts that supports both chemistry, manufacturing, and controls (CMC) submissions for a planned NDA and commercial supply [14] Future Outlook - Near-term priorities include top-line data from the Phase 3 LUGANO wet AMD trial anticipated in mid-2026, with LUCIA data closely following, and completing enrollment in the pivotal Phase 3 DME program in the second half of 2026 [21]

Financial Data and Key Metrics Changes - The company ended 2025 with a strong balance sheet of $306 million in cash and investments, down from $371 million as of December 31, 2024 [17] - Total net revenue for Q4 2025 was $0.6 million, a significant decrease from $11.6 million in Q4 2024, primarily due to the recognition of remaining deferred revenue related to the YUTIQ product rights [15] - For the full year 2025, total net revenue was $31 million, compared to $43 million in 2024, again driven by the deferred revenue recognition [16] - Operating expenses for Q4 2025 totaled $71 million, up from $57 million in the prior year, mainly due to ongoing Phase 3 trials for DURAVYU [16] - The net loss for Q4 2025 was approximately $68 million or $0.81 per share, compared to a net loss of $41 million or $0.64 per share in the prior year [16] Business Line Data and Key Metrics Changes - DURAVYU is on track to deliver top-line data in wet AMD beginning in mid-2026, with the first patients dosed in pivotal Phase 3 DME trials [7][8] - The company is focused on building DURAVYU into a durable franchise targeting the largest retinal disease markets, which have a combined current global market of $10 billion [12] Market Data and Key Metrics Changes - The global market for wet AMD and DME is currently valued at $10 billion and is expected to grow, highlighting the significant commercial potential for DURAVYU [12] Company Strategy and Development Direction - The company aims to position DURAVYU as the first to market among current investigational sustained release programs in both wet AMD and DME, with a potential best-in-class profile [11] - The strategy includes a focus on a de-risked, clinically rigorous, and patient-centric approach to drug development [19] - The company is preparing for a potential U.S. launch of DURAVYU, with a strong emphasis on commercial readiness and operational expansion [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in DURAVYU's blockbuster potential, supported by its compelling clinical profile and favorable safety data [8] - The company is well-capitalized to continue advancing DURAVYU through late-stage development programs, with cash expected to fund operations into Q4 2027 [18] - Management highlighted the importance of upcoming milestones, including reporting top-line data for the Phase 3 LUGANO trial anticipated in mid-2026 [19] Other Important Information - The company welcomed Michael Campbell as the new Chief Commercial Officer, who brings extensive experience in product launches and oversight of ophthalmology franchises [12] - The company is expanding operations at its cGMP manufacturing facility in Massachusetts, which supports both NDA submissions and commercial supply [13] Q&A Session Summary Question: Can you clarify the rate of ocular AEs seen with DURAVYU, particularly around vitreous floaters and cataracts? - The incidence of cataracts in treated patients was 5.8%, while vitreous floaters were reported in 5.2% of patients, consistent with expectations for injection studies [24][26] Question: How are you thinking about recent FDA chatter around single study-driven regulatory approvals? - The company welcomes a more rapid pathway to drug approvals but does not anticipate changing its strategy for current trials [32][34] Question: Will there be additional looks at masked safety in the wet AMD trials before they read out? - The company has ongoing internal and independent Data Safety Monitoring Committee reviews, with the next meeting scheduled for May [39] Question: What is the expected safety profile in LUGANO LUCIA compared to DAVIO 2? - The company does not expect significant differences in safety profiles, as the insert design and drug dosage have been optimized [75][78] Question: How do you expect the steps or requirements to affect the adoption of vorolanib? - Initial adoption is expected among patients requiring frequent treatments, with broader adoption possible if clinical trials demonstrate superior efficacy [91][94]

Financial Data and Key Metrics Changes - The company ended 2025 with a strong balance sheet of $306 million in cash and investments, down from $371 million as of December 31, 2024 [17] - For Q4 2025, total net revenue was $0.6 million, a significant decrease from $11.6 million in Q4 2024, primarily due to the recognition of remaining deferred revenue related to the YUTIQ product rights [15] - Full year 2025 total net revenue was $31 million, compared to $43 million in 2024, again driven by the deferred revenue recognition [16] - Operating expenses for Q4 2025 totaled $71 million, up from $57 million in the prior year, mainly due to ongoing Phase III trials for DURAVYU [16] - The net loss for Q4 2025 was approximately $68 million or $0.81 per share, compared to a net loss of $41 million or $0.64 per share in the prior year [16] Business Line Data and Key Metrics Changes - DURAVYU is on track to deliver top-line data in wet AMD beginning in mid-2026, with the first patients dosed in pivotal Phase III DME trials [7][8] - The company is focused on building DURAVYU into a durable franchise targeting the largest retinal disease markets, which have a combined current global market of $10 billion [12] Market Data and Key Metrics Changes - The global market for wet AMD and DME is currently valued at $10 billion and is expected to grow [12] Company Strategy and Development Direction - The company aims to position DURAVYU as the first to market among current investigational sustained release programs in both wet AMD and DME, with a potential best-in-class profile [11] - The strategy includes a focus on commercial readiness and the appointment of a new Chief Commercial Officer to prepare for a successful U.S. launch [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in DURAVYU's blockbuster potential, citing its compelling clinical profile and favorable safety profile observed in over 190 patients across four completed clinical trials [8][9] - The company is well-capitalized to continue advancing DURAVYU through late-stage development programs, with cash expected to fund operations into Q4 2027 [18] Other Important Information - The company is preparing for regulatory submission and pre-approval inspection as it nears NDA submission for DURAVYU [13] Q&A Session Summary Question: Can you clarify the rate of ocular AEs seen with DURAVYU, particularly around vitreous floaters and cataracts? - The incidence of cataracts in treated patients was 5.8%, while vitreous floaters were reported in 5.2% of patients, consistent with expectations for injection studies [24][26] Question: How are you thinking about recent FDA chatter around single study-driven regulatory approvals? - The company welcomes a more rapid pathway to drug approvals but does not anticipate changing its strategy for current trials [32] Question: Will there be additional looks at masked safety in the wet AMD trials before they read out? - There will be ongoing safety monitoring by both internal and independent committees, with the next review scheduled for May [39] Question: What are the expectations for the reduction in treatment burden in the wet AMD studies? - The treatment burden will be measured after the loading doses, with expectations of a 60% reduction in the DURAVYU arm compared to the control arm [69] Question: How do you expect the steps or requirements to affect the adoption of vorolanib? - Initial adoption is expected among patients requiring frequent treatments, with potential expansion based on clinical trial outcomes [92]

Financial Data and Key Metrics Changes - For Q4 2025, total net revenue was $0.6 million, a decrease from $11.6 million in Q4 2024, primarily due to the recognition of remaining deferred revenue related to the YUTIQ product rights license [14][15] - Full year 2025 total net revenue was $31 million, down from $43 million in 2024, again attributed to the deferred revenue recognition [16][17] - Operating expenses for Q4 2025 totaled $71 million, up from $57 million in the prior year, driven by ongoing Phase 3 trials for DURAVYU [16] - Full year operating expenses reached $275 million, compared to $189 million in 2024, reflecting increased trial costs [17] - Net loss for Q4 2025 was approximately $68 million or $0.81 per share, compared to a net loss of $41 million or $0.64 per share in Q4 2024 [16] - Full year net loss was $232 million or $3.17 per share, compared to a net loss of $131 million or $2.32 per share in 2024 [17] - Cash and investments as of December 31, 2025, totaled $306 million, down from $371 million at the end of 2024, expected to fund operations into Q4 2027 [17][18] Business Line Data and Key Metrics Changes - DURAVYU is positioned as a leading asset with pivotal Phase 3 trials for wet AMD and DME, with first patient dosing reported [5][10] - The company anticipates top-line data for the wet AMD program in mid-2026 and for the DME program in the second half of 2027 [10][19] Market Data and Key Metrics Changes - The combined global market for wet AMD and DME is estimated at $10 billion and growing, representing a significant opportunity for DURAVYU [11] Company Strategy and Development Direction - The company aims to establish DURAVYU as a durable franchise targeting the largest retinal disease markets, focusing on its unique multi-mechanism of action and favorable safety profile [10][11] - The strategy includes preparing for a potential U.S. launch and expanding commercial readiness with the appointment of a new Chief Commercial Officer [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in DURAVYU's potential, citing strong clinical data and a favorable safety profile, with no safety signals reported in over 190 patients across completed trials [6][27] - The company is optimistic about upcoming milestones and the transformative potential of DURAVYU in the retinal disease market [13][19] Other Important Information - The company is expanding its cGMP manufacturing facility to support commercial supply and regulatory submissions [12] - Management emphasized the importance of a de-risked, clinically rigorous, and patient-centric approach in advancing DURAVYU [19] Q&A Session Summary Question: Can you clarify the rate of ocular AEs seen with DURAVYU, particularly around vitreous floaters and cataracts? - The incidence of cataracts in treated patients was 5.8%, with vitreous floaters reported at 5.2%, consistent with injection studies [25][26] Question: How are you thinking about recent FDA chatter around single study-driven regulatory approvals? - The company welcomes a more rapid approval pathway but does not anticipate altering its current strategy for wet AMD and DME [31][32] Question: Will there be additional looks at masked safety in the wet AMD trials before they read out? - There will be ongoing safety reviews by both internal and independent committees, with the next review scheduled for May [39] Question: What are the expectations for the reduction in treatment burden in the wet AMD studies? - The treatment burden will be measured after the loading doses, with expectations of a 60% reduction in the DURAVYU arm compared to the control [68][70] Question: How do you expect the steps or requirements to affect the adoption of vorolanib? - Initial adoption is expected among patients requiring frequent treatments, with potential expansion based on clinical trial outcomes [90][92]

Core Insights - EyePoint, Inc. is advancing its pivotal Phase 3 trials for DURAVYU in wet age-related macular degeneration (AMD) and diabetic macular edema (DME), with data readouts expected to begin in mid-2026 [1][2] - The company has appointed Michael Campbell as Chief Commercial Officer to lead the launch strategy for DURAVYU [1] - As of December 31, 2025, EyePoint reported over $300 million in cash and investments, providing financial stability into Q4 2027 [1][12] Clinical Development - DURAVYU is currently in two identical Phase 3 trials, LUGANO and LUCIA, for wet AMD, with over 900 patients enrolled [4] - The trials are designed to follow a non-inferiority pathway with an on-label aflibercept control arm and six-month re-dosing [4] - Interim safety data from the trials has shown a consistent favorable safety profile [4] - The first patients have been dosed in the COMO and CAPRI Phase 3 trials for DME, with rapid enrollment expected [4] Financial Performance - For Q4 2025, total net revenue was $0.6 million, a significant decrease from $11.6 million in Q4 2024 [6] - Net product revenue for Q4 2025 was $0.3 million, down from $0.8 million in the same period of 2024 [6] - Total net revenue for the full year 2025 was $31.4 million, compared to $43.3 million in 2024 [9] - Operating expenses for Q4 2025 totaled $71.0 million, up from $56.8 million in the prior year, primarily due to ongoing Phase 3 trials [8][11] Corporate Developments - EyePoint has expanded its intellectual property protection for DURAVYU with a new U.S. patent expected to extend coverage into 2043 [10] - The company completed manufacturing of registration batches for DURAVYU, which will support the New Drug Application (NDA) filing [10] - An underwritten public offering in October 2025 raised gross proceeds of $172.5 million [10]

Summary of EyePoint Pharmaceuticals FY Conference Call Company Overview - **Company**: EyePoint Pharmaceuticals (NasdaqGM:EYPT) - **Industry**: Biotechnology, specifically focusing on ophthalmology and treatments for retinal diseases Key Highlights - **Phase 3 Trials Initiation**: EyePoint announced the dosing of patients in both phase 3 diabetic macular edema (DME) trials, COMO and CAPRI, achieving their timeline goal of first patient dosing in Q1 2026 [2][3] - **Market Opportunity**: The DME market is projected to reach $3 billion annually in the U.S. EyePoint aims to capture a significant share of this market with their sustained release TKI, DURAVYU, which is unique in the DME space [2][3] - **Trial Design**: Each DME trial will enroll approximately 240 patients, leveraging safety data from previous wet AMD trials to maintain a lower patient count while ensuring robust results [3][5] Core Points and Arguments - **Efficacy and Safety**: DURAVYU demonstrated superior results compared to EYLEA in phase 2 trials, with patients showing better visual acuity and less fluid accumulation [4][21] - **Recruitment Success**: The company successfully recruited for their wet AMD trials in about 7 months, indicating strong interest and confidence from clinical sites, which will also be utilized for the DME trials [5][6] - **Safety Profile**: No serious adverse events (SAEs) have been reported in the 191 patients treated across four trials, reinforcing confidence in the safety of DURAVYU [22] Mechanistic Insights - **IL-6 Blockade Discovery**: EyePoint identified that DURAVYU acts as a potent blocker of JAK1, which is linked to IL-6 activity, potentially providing additional therapeutic benefits in treating DME and wet AMD [15][19] - **Differentiation from Competitors**: EyePoint's approach combines anti-VEGF and anti-IL-6 mechanisms, which may offer advantages over existing treatments [19][60] Phase 3 Expectations - **Non-Inferiority and Treatment Burden**: The primary endpoint for phase 3 trials is non-inferiority to EYLEA, with a secondary focus on reducing treatment burden. A 60% reduction in treatment burden is anticipated compared to EYLEA's regimen [28][29] - **Supplementation Criteria**: Improved criteria for supplemental injections are expected to lead to fewer unnecessary supplements in the phase 3 trials, enhancing overall treatment efficiency [32][33] Market Potential - **Combined Market Size**: The total market opportunity for wet AMD and DME is estimated at $15 billion globally, with EyePoint targeting a significant share if they can demonstrate non-inferiority and additional benefits [68] - **Long-term Patient Compliance**: The sustained release nature of DURAVYU is expected to improve patient compliance and outcomes, addressing a critical issue in chronic disease management [49][50] Additional Insights - **Regulatory Strategy**: EyePoint is preparing for potential NDA submissions following the completion of their trials, with expectations of a streamlined process due to the identical nature of the studies [38][39] - **Future Developments**: The company plans to present more data at upcoming conferences, which may further validate their findings and enhance market perception [19][68] This summary encapsulates the key points discussed during the conference call, highlighting EyePoint Pharmaceuticals' strategic direction, market potential, and innovative approaches in the treatment of retinal diseases.

Core Insights - EyePoint, Inc. has initiated Phase 3 clinical trials for DURAVYU, an investigational treatment for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), marking a significant milestone in retinal disease therapeutics [2][3][10] - DURAVYU is designed to provide sustained drug delivery for at least six months, potentially reducing the treatment burden for patients [3][5][9] Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, with DURAVYU as its lead product candidate [10][11] - The company is headquartered in Watertown, Massachusetts, and has a commercial manufacturing facility in Northbridge, Massachusetts [11] Product Details - DURAVYU (vorolanib intravitreal insert) is a sustained-delivery therapy that combines a selective tyrosine kinase inhibitor (TKI) with advanced delivery technology to target multiple mechanisms of action in retinal diseases [5][6] - The treatment aims to address both VEGF-mediated vascular leakage and IL-6 mediated inflammation, which are critical in the pathology of DME [6][9] Clinical Trials - The Phase 3 trials, COMO and CAPRI, will enroll approximately 240 patients each, comparing DURAVYU to aflibercept, a current standard of care [3][9] - Topline data for the DME trials is expected in the second half of 2027, while data for the wet AMD trials is anticipated to begin reporting in mid-2026 [1][9][10] Market Context - Diabetic macular edema is a leading cause of vision loss among diabetic patients, affecting approximately 28 million people globally, highlighting the urgent need for effective treatment options [4][10] - Current treatments often involve burdensome frequent injections, which DURAVYU aims to alleviate through its sustained-release mechanism [4][9]

Core Viewpoint - EyePoint, Inc. is set to report its fourth quarter and full-year 2025 financial results on March 4, 2026, highlighting recent corporate developments [1] Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases [3] - The company's lead product candidate, DURAVYU, is an investigational sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E technology [3] - DURAVYU is currently undergoing Phase 3 pivotal trials for wet age-related macular degeneration, with topline data expected in mid-2026, and first patient dosing in diabetic macular edema trials anticipated in Q1 2026 [3] Product and Development - Vorolanib is exclusively licensed to EyePoint for localized treatment of ophthalmic diseases outside of specific regions in Asia [5] - DURAVYU has received conditional acceptance from the FDA as the proprietary name for EYP-1901, although it remains an investigational product and has not yet been approved by the FDA [5] Commitment to Community - The company aims to partner with the retina community to enhance patient lives while creating long-term value, having developed four approved drugs over three decades and treated tens of thousands of patients [4]